Related Experiment Video
Updated: Jul 13, 2026
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Effects of IL-12 gene therapy on spontaneous transgenic and transplanted breast tumors
Francesca Faggioli1, Sabina Soldati, Eugenio Scanziani
1Istituto di Tecnologie Biomediche, CNR, Segrate, Milan, Italy.
Abstract:
Cytokines are promising agents for cancer therapy due to their activity at low concentrations. We used a naked IL-12 DNA expression vector to achieve long-term systemic cytokine expression to inhibit breast tumor growth in MMTVneu transgenic and transplanted models. Constant low levels of IL-12 produced by this protocol provided effective tumor growth inhibition of both tumor models without adverse effects.
Insights
This study shows that low, sustained levels of Interleukin-12 (IL-12) effectively inhibit breast tumor growth in mouse models. This cytokine therapy approach demonstrated efficacy without causing adverse effects.
Area of Science:
- Oncology
- Immunotherapy
- Gene Therapy
Background:
- Cytokines show promise for cancer treatment due to their potent activity at low concentrations.
- Interleukin-12 (IL-12) is a cytokine with known anti-tumor properties.
- Developing effective delivery methods for sustained cytokine expression is crucial for therapeutic success.
Purpose of the Study:
- To evaluate the efficacy of a naked DNA expression vector for long-term systemic Interleukin-12 (IL-12) expression.
- To assess the potential of IL-12 gene therapy to inhibit breast tumor growth in preclinical models.
- To determine if sustained low-level IL-12 expression impacts tumor progression or causes adverse effects.
Main Methods:
- Utilized a naked DNA expression vector encoding for IL-12.
- Administered the vector to MMTVneu transgenic mice and in transplanted tumor models.
- Monitored tumor growth and assessed for adverse effects.
Main Results:
- Achieved long-term, systemic expression of IL-12 at constant low levels.
- Demonstrated effective inhibition of breast tumor growth in both transgenic and transplanted models.
- Observed no significant adverse effects associated with the IL-12 gene therapy protocol.
Conclusions:
- Naked IL-12 DNA expression vectors can achieve sustained systemic cytokine levels for cancer therapy.
- This approach provides effective inhibition of breast tumor growth.
- IL-12 gene therapy is a promising strategy for breast cancer treatment with a favorable safety profile.
